ACADIA Pharmaceuticals Inc. (ACAD)
NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
As of 10:47AM EDT. Market open.
| Previous close | 17.05 |
| Open | 16.94 |
| Bid | 17.16 x 300 |
| Ask | 17.27 x 300 |
| Day's range | 16.81 - 17.25 |
| 52-week range | 16.16 - 33.99 |
| Volume | |
| Avg. volume | 1,812,929 |
| Market cap | 2.843B |
| Beta (5Y monthly) | 0.39 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Simply Wall St.
ACADIA Pharmaceuticals (NASDAQ:ACAD) shareholders have endured a 37% loss from investing in the stock five years ago
In order to justify the effort of selecting individual stocks, it's worth striving to beat the returns from a market...
- GuruFocus.com
ACADIA Pharmaceuticals Inc CEO Stephen Davis Sells 26,574 Shares
ACADIA Pharmaceuticals Inc (NASDAQ:ACAD), a biopharmaceutical company focused on the development and commercialization of medicines to address unmet medical needs in central nervous system disorders, has reported an insider sell transaction.
- GuruFocus.com
ACADIA Pharmaceuticals Inc CEO Stephen Davis Sells 17,714 Shares
Stephen Davis, the CEO of ACADIA Pharmaceuticals Inc (NASDAQ:ACAD), has sold 17,714 shares of the company on March 27, 2024, according to a recent SEC filing.
© 2024 Yahoo. All rights reserved.